Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
Zacks' 7 Best Stocks
for June, 2013
FREE Report for Zacks.com
Visitors Only
Visitors Only
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
- Latest News
- Most Popular
- Roundtable Top Picks of the Week
- FED Front & Center Again
- RTI: Sector Strength Charts - Where's the Opportunity Now?
- Surging Financial ETFs Beating the Market
- Utility Industry Stock Outlook - June 2013
- 3 Japanese Stocks to Buy Now
- Your Next Stock Should Be Making New Highs
- Anatomy of Success: Stoneridge (SRI)
- RTI: What Will the Fed Do Wednesday?
- AWS 6/18: Can the Fed Afford to Keep the Suspense?
- PFP 6/18: Wednesday Fed Watch
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 06/18/2013
| Company Name | Symbol | %Change |
|---|---|---|
| STAAR SURGIC | STAA | 10.98% |
| DTS INC | DTSI | 6.89% |
| ANIKA THERAP | ANIK | 6.04% |
| LUMOS NETWOR | LMOS | 5.70% |
| INSTEEL IND | IIIN | 5.28% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Company Description
STAAR Surgical makes minimally invasive ophthalmic implantable lenses as an alternative to LASIK. The company also has lenses to replace the eye's natural lens after cataract surgery.
Seeing Green
On Aug 2 the company reported a 19% increase in revenue, to $16.3 million. STAAR also saw its margins improve to a 13-year high, which led to the better than expected earnings results.
Earnings per share came in at $0.02, edging out the Zacks Consensus Estimate by a penny. Net income was just around $862 thousand, up from a $1.6 million loss a year ago.
Additionally, the company showed a stronger balance sheet, increasing its cash balance to over $13 million.
Analysts Getting Bullish
Estimates inched a couple cents higher and are now averaging $0.08 per share for the year. Compare that to a 9-cent loss in 2010.
While next year's estimates are unchanged, averaging $0.14, that is still good enough for an 81% growth rate.
Growth, but Not Value
When seeing the EPS counted in pennies rather than dollars it is tough to find good P/E ratios. Also, the company's P/S is well over 4 times.
But, there is a clear growth story here and as long as estimates keep rising the stock should as well. STAAR is looking to cash in on 4 new products that received regulatory approval so far this year that should bolster the improving cash flows. The company also went on to raise its revenue outlook for the rest of the year.
Defensive?
Healthcare is often one of the go-to industries for those looking to get defensive holdings. STAA may not fall into that category but it does have a niche market and a great outlook.
The Chart
Those valuations I mentioned earlier here largely due to the stock going gangbusters in August, so many would opt to wait for a pull back. But, with 73% or so owned by institutions and insiders there may not be many sellers out there.
Bill Wilton is the Aggressive Growth Stock Strategist for Zacks.com. He is also the Editor in charge of the Zacks Small Cap Trader service
Get the full Snapshot Report on STAA - FREE